RBC Capital Markets analyst Randall Stanicky sees lots of reasons Allergan should pursue a breakup. A women’s health sale that could bring in billions is just one of them.
The way he sees it, Allergan’s women’s health unit is a “~$1 billion revenue franchise.” But if the Dublin drugmaker were to sell it off? The company would have plenty of takers, Stanicky figures, and potentially $6 billion in deal proceeds when all was said and done.
For one, Impax—helmed by former Allergan chairman and Actavis CEO Paul Bisaro—has “stated interest,” Stanicky says, and as the former owner of the women’s health assets, Bisaro knows exactly what he’s dealing with. Lupin, which is looking to play in the women’s health space, could be another possibility, and so could CooperSurgical, which recently snapped up Teva’s Paragard intrauterine copper contraceptive for $1.1 billion.
Then there’s Mylan, which has a “sizeable” women’s health lineup that it last added to in 2015 with a buy of Famy Care. And don’t count out private equity players, either; they’ve been “active recently in the area,” Stanicky notes.
But just because there’s potential interest doesn’t mean Allergan’s necessarily ready to take Stanicky’s advice—and in fact, CEO Brent Saunders has told investors that it isn’t planning to. “Splitting the company is … at least a few years of work, and that’s not something that we’re focused on right now,” he said earlier this month on the company’s third-quarter conference call.
Those remarks didn’t dampen Stanicky’s enthusiasm for a split, though—and according to him, they haven’t dampened investors’ enthusiasm, either. “We continue to hear investor support for potential breakup/split to unlock value, which we think is inevitable,” he wrote to clients on Monday, adding that he thinks that support is actually increasing.
One reason? “More robust Growth-co assets are being diluted by Mature-co,” he figures, with women’s health, gastroenterology and anti-infectives comprising Allergan’s “noncore” assets. He’s “not convinced” of the benefits to selling products in those areas alongside Allergan’s aesthetics moneymakers and pointed out that the setup is the result of M&A transactions past.
“If AGN were establishing a new platform today, it is hard to imagine this would be the ‘ideal’ asset mix it would pursue,” he wrote. “… That should have long-term investors questioning why the platform is not being addressed more aggressively.”
By Carly Helfand
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”